|Bid||6.54 x 800|
|Ask||6.64 x 1800|
|Day's range||6.05 - 6.63|
|52-week range||2.14 - 6.87|
|Beta (5Y monthly)||-0.55|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021 - 15 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.90|
BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.
LAVAL, Quebec, September 23, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough ("RCC") and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic prur
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.